Cancer Research6d
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Cancer Research7d
Comparison of Shared Class I HLA-bound Non-canonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Cancer Research7d
Novel Degrader Shows Anti–Lymphoma and Myeloma Activity
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
Cancer Research7d
Stratified Medicine Paediatrics: Cell free DNA and serial tumour sequencing identifies subtype specific cancer evolution and epigenetic states
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Cancer Research7d
EZH2 Inhibition Enhances T-cell Immunotherapy in B Cell Lymphoma
Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...
Cancer Research7d
ALK TKI Earns FDA Approval
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...